L'evaluation de plongeurs pediatriques prospectifs a ete largement basee sur des opinions, le... more L'evaluation de plongeurs pediatriques prospectifs a ete largement basee sur des opinions, les donnees etant limitees. Nous avons des lors entrepris une etude afin d'etablir et d'evaluer un systeme d'initiation a la plongee en scaphandre autonome pour les enfants, sur base d'un club de plongee pour enfants, Les Marmottes et Castors Palmes, Bruxelles, Belgique. Les caracteristiques respiratoires, cardiovasculaires, ORL, musculo-squelettiques et thermoregulatrices des enfants influencent leur capacite a faire face a l'environnement subaquatique. En plongee, les enfants ont leurs propres besoins specifiques. Avant l'âge de 7 a 8 ans, il existe des risques de dyspnee, d'hypoxie et de barotraumatisme pulmonaire en raison de l'immaturite des poumons. L'autorisation medicale de plonger n'a ete accordee qu'apres une evaluation basee sur une approche en equipe associant medecins, parents et instructeurs, en tenant compte de ces differents facte...
ABSTRACT Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with n... more ABSTRACT Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with no agonist effects. The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy. Fifty-seven postmenopausal women with ER and/or progesterone receptor-positive ABC resistant to previous endocrine treatments prospectively received fulvestrant 250 mg via intramuscular injection q 28. Twenty-seven patients received fulvestrant after PD and 30 received it as maintenance therapy after chemotherapy. All patients received fulvestrant as second-up to eight-line endocrine treatment for ABC. One patient (2%) had a partial response (PR) and 24 patients (42%) had stable disease > or =12 weeks (SD), including 11 patients who had SD > or =24 weeks. Thirty-two patients (56%) had de novo PD. Clinical benefit (CB; PR + SD > or =24 weeks) occurred in 12 patients (21%). Patients treated as maintenance and treated upon PD had 0 and 4% PR, 43 and 41% SD (including 20 and 19% SD > or =24 weeks), 57 and 55% PD, respectively. Overall, median time to progression (TTP) was 3 months. No differences in CB rate (20% vs. 23%), TTP (3 months vs. 3 months) and time to treatment failure (3 months vs. 3 months) were observed between patients receiving fulvestrant as maintenance therapy and those treated at PD on prior endocrine treatment. No grade 2-4 NCI-CTC toxicity was recorded. Fulvestrant treatment was associated with prolonged CB and was well tolerated in this group of heavily pre-treated patients with ABC. The outcomes appeared to be similar for patients treated upon PD and those receiving fulvestrant as maintenance therapy.
The safety and efficacy of subgingivally-applied 2% minocycline ointment was evaluated in a rando... more The safety and efficacy of subgingivally-applied 2% minocycline ointment was evaluated in a randomized, double-blind study of 103 adults with moderate to severe periodontitis. Two groups were compared; one received the test minocycline ointment and the other a vehicle control. Both groups had scaling and root planing at baseline, after which the test or control ointments were applied with an applicator into the periodontal pockets at baseline, and at 2, 4, and 6 weeks. Assessment of clinical response was made by measuring probing depth and probing attachment level and gingival bleeding. These measurements were made at baseline prior to scaling and root planing, and at weeks 4 and 12. Microbiological assessment of the subgingival flora was carried out with DNA probes at baseline, and at weeks 2, 4, 6, and 12 to identify and quantify Porphyromonas gingivalis, Prevotella intermedia, and Actinobacillus actinomycetemcomitans. Subgingival minocycline ointment resulted in statistically significantly greater reduction of P. gingivalis at weeks 2, 4, 6, and 12; P. intermedia at weeks 2, 4, 6, and 12; and A. actinomycetemcomitans at weeks 6 and 12. Probing depth reductions were seen for both groups at weeks 4 and 12; however, this reduction was statistically significantly greater in subjects treated with minocycline ointment. Reduction in gingival index and probing attachment gain were seen in both groups, however, the differences between the groups were not statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)
... ITEM METADATA RECORD. Title: Methodological lessons learned from a multicenter trial of Helic... more ... ITEM METADATA RECORD. Title: Methodological lessons learned from a multicenter trial of Helicobacter pylori infection using centralised laboratory facilities. Authors: Glupczynski, Y Ectors, Nadine Burette, A Noë, M Laruelle, N Vandenhoven, G. Issue Date: 1997. ...
... Title, Belgian evaluation of screening and treatment of high risk patients based on waist and... more ... Title, Belgian evaluation of screening and treatment of high risk patients based on waist and age (BEST): Focus on diabetes mellitus and metabolic syndrome. Publication Status, published. ... Volume, 54. Department, GE12 - Department of Public health. Source, aleph:pug01. ...
Discovery Belux is an open-label, multicentre, randomised, phase IIIb, parallel group study compa... more Discovery Belux is an open-label, multicentre, randomised, phase IIIb, parallel group study comparing the efficacy of rosuvastatin (RSV) and atorvastatin (ATV) on changes in lipid levels and the achievement of European Atherosclerosis Society (EAS) lipid goals. Patients (> or = 18 years) with primary hypercholesterolaemia, with a low-density lipoprotein (LDL-C) level > 120 mg/dl (on treatment) or > 135 mg/dl (naive subjects), and with a statin indication, were randomised to receive RSV 10 mg/day or ATV 10 mg/day for 12 weeks. Patients not at goal after 12 weeks and receiving ATV 10 were further switched to RSV 10 mg for another 12 weeks. Patients not at goal with RSV 10 mg were further titrated to RSV 20 mg. 938 patients were randomised to the two treatment groups. After 12 weeks of treatment, a significantly greater percentage of patients receiving RSV 10 compared with ATV 10 achieved EAS LDL-C target goal (< 115 mg/dl) (85% vs. 67%). LDL-C was reduced by 47% and total cholesterol (TC) by 33% with RSV 10.This was 38% and 27% for ATV 10, respectively. After 24 weeks, an additional 57% of patients initially taking RSV 10 and uncontrolled, reached the target with RSV 20. In the patient group, initially taking ATV 10 and uncontrolled, 65% reached the target with RSV 10 after 24 weeks. Both treatments were well tolerated with a similar incidence of adverse events. In addition, a health economic analysis was performed. As RSV 10 is available at a lower cost in Belgium and as it is more effective, compared to ATV 10, it appeared to be the option of choice from a cost-effectiveness perspective. Rosuvastatin 10 mg treatment is significantly more effective than atorvastatin 10 mg at achieving European LDL-C goals, at lowering LDL-C and TC. These results were obtained with a similar safety profile. From a cost-effectiveness perspective RSV 10 is the preferred therapeutic option in comparison with ATV 10. Uptitration of uncontrolled patients to RSV 20 mg and switch from ATV 10 to RSV 10 allowed significantly more patients to reach the LDL-C and TC target goal.
L'evaluation de plongeurs pediatriques prospectifs a ete largement basee sur des opinions, le... more L'evaluation de plongeurs pediatriques prospectifs a ete largement basee sur des opinions, les donnees etant limitees. Nous avons des lors entrepris une etude afin d'etablir et d'evaluer un systeme d'initiation a la plongee en scaphandre autonome pour les enfants, sur base d'un club de plongee pour enfants, Les Marmottes et Castors Palmes, Bruxelles, Belgique. Les caracteristiques respiratoires, cardiovasculaires, ORL, musculo-squelettiques et thermoregulatrices des enfants influencent leur capacite a faire face a l'environnement subaquatique. En plongee, les enfants ont leurs propres besoins specifiques. Avant l'âge de 7 a 8 ans, il existe des risques de dyspnee, d'hypoxie et de barotraumatisme pulmonaire en raison de l'immaturite des poumons. L'autorisation medicale de plonger n'a ete accordee qu'apres une evaluation basee sur une approche en equipe associant medecins, parents et instructeurs, en tenant compte de ces differents facte...
ABSTRACT Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with n... more ABSTRACT Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with no agonist effects. The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy. Fifty-seven postmenopausal women with ER and/or progesterone receptor-positive ABC resistant to previous endocrine treatments prospectively received fulvestrant 250 mg via intramuscular injection q 28. Twenty-seven patients received fulvestrant after PD and 30 received it as maintenance therapy after chemotherapy. All patients received fulvestrant as second-up to eight-line endocrine treatment for ABC. One patient (2%) had a partial response (PR) and 24 patients (42%) had stable disease > or =12 weeks (SD), including 11 patients who had SD > or =24 weeks. Thirty-two patients (56%) had de novo PD. Clinical benefit (CB; PR + SD > or =24 weeks) occurred in 12 patients (21%). Patients treated as maintenance and treated upon PD had 0 and 4% PR, 43 and 41% SD (including 20 and 19% SD > or =24 weeks), 57 and 55% PD, respectively. Overall, median time to progression (TTP) was 3 months. No differences in CB rate (20% vs. 23%), TTP (3 months vs. 3 months) and time to treatment failure (3 months vs. 3 months) were observed between patients receiving fulvestrant as maintenance therapy and those treated at PD on prior endocrine treatment. No grade 2-4 NCI-CTC toxicity was recorded. Fulvestrant treatment was associated with prolonged CB and was well tolerated in this group of heavily pre-treated patients with ABC. The outcomes appeared to be similar for patients treated upon PD and those receiving fulvestrant as maintenance therapy.
The safety and efficacy of subgingivally-applied 2% minocycline ointment was evaluated in a rando... more The safety and efficacy of subgingivally-applied 2% minocycline ointment was evaluated in a randomized, double-blind study of 103 adults with moderate to severe periodontitis. Two groups were compared; one received the test minocycline ointment and the other a vehicle control. Both groups had scaling and root planing at baseline, after which the test or control ointments were applied with an applicator into the periodontal pockets at baseline, and at 2, 4, and 6 weeks. Assessment of clinical response was made by measuring probing depth and probing attachment level and gingival bleeding. These measurements were made at baseline prior to scaling and root planing, and at weeks 4 and 12. Microbiological assessment of the subgingival flora was carried out with DNA probes at baseline, and at weeks 2, 4, 6, and 12 to identify and quantify Porphyromonas gingivalis, Prevotella intermedia, and Actinobacillus actinomycetemcomitans. Subgingival minocycline ointment resulted in statistically significantly greater reduction of P. gingivalis at weeks 2, 4, 6, and 12; P. intermedia at weeks 2, 4, 6, and 12; and A. actinomycetemcomitans at weeks 6 and 12. Probing depth reductions were seen for both groups at weeks 4 and 12; however, this reduction was statistically significantly greater in subjects treated with minocycline ointment. Reduction in gingival index and probing attachment gain were seen in both groups, however, the differences between the groups were not statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)
... ITEM METADATA RECORD. Title: Methodological lessons learned from a multicenter trial of Helic... more ... ITEM METADATA RECORD. Title: Methodological lessons learned from a multicenter trial of Helicobacter pylori infection using centralised laboratory facilities. Authors: Glupczynski, Y Ectors, Nadine Burette, A Noë, M Laruelle, N Vandenhoven, G. Issue Date: 1997. ...
... Title, Belgian evaluation of screening and treatment of high risk patients based on waist and... more ... Title, Belgian evaluation of screening and treatment of high risk patients based on waist and age (BEST): Focus on diabetes mellitus and metabolic syndrome. Publication Status, published. ... Volume, 54. Department, GE12 - Department of Public health. Source, aleph:pug01. ...
Discovery Belux is an open-label, multicentre, randomised, phase IIIb, parallel group study compa... more Discovery Belux is an open-label, multicentre, randomised, phase IIIb, parallel group study comparing the efficacy of rosuvastatin (RSV) and atorvastatin (ATV) on changes in lipid levels and the achievement of European Atherosclerosis Society (EAS) lipid goals. Patients (> or = 18 years) with primary hypercholesterolaemia, with a low-density lipoprotein (LDL-C) level > 120 mg/dl (on treatment) or > 135 mg/dl (naive subjects), and with a statin indication, were randomised to receive RSV 10 mg/day or ATV 10 mg/day for 12 weeks. Patients not at goal after 12 weeks and receiving ATV 10 were further switched to RSV 10 mg for another 12 weeks. Patients not at goal with RSV 10 mg were further titrated to RSV 20 mg. 938 patients were randomised to the two treatment groups. After 12 weeks of treatment, a significantly greater percentage of patients receiving RSV 10 compared with ATV 10 achieved EAS LDL-C target goal (< 115 mg/dl) (85% vs. 67%). LDL-C was reduced by 47% and total cholesterol (TC) by 33% with RSV 10.This was 38% and 27% for ATV 10, respectively. After 24 weeks, an additional 57% of patients initially taking RSV 10 and uncontrolled, reached the target with RSV 20. In the patient group, initially taking ATV 10 and uncontrolled, 65% reached the target with RSV 10 after 24 weeks. Both treatments were well tolerated with a similar incidence of adverse events. In addition, a health economic analysis was performed. As RSV 10 is available at a lower cost in Belgium and as it is more effective, compared to ATV 10, it appeared to be the option of choice from a cost-effectiveness perspective. Rosuvastatin 10 mg treatment is significantly more effective than atorvastatin 10 mg at achieving European LDL-C goals, at lowering LDL-C and TC. These results were obtained with a similar safety profile. From a cost-effectiveness perspective RSV 10 is the preferred therapeutic option in comparison with ATV 10. Uptitration of uncontrolled patients to RSV 20 mg and switch from ATV 10 to RSV 10 allowed significantly more patients to reach the LDL-C and TC target goal.
Uploads
Papers by G. Vandenhoven